Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s441, 2024. DOI: 10.25251/skin.8.supp.441. Disponível em: https://skin.dermsquared.com/skin/article/view/3139. Acesso em: 4 apr. 2025.